FDA Reverses Course, Agrees to Review Moderna's Flu Vaccine Application
The U.S. Food and Drug Administration has reversed its earlier decision and will now review Moderna's application for its modified influenza vaccine.
Results for “D.A.”
3 stories found
Rivian’s stock just had its best day ever — and now this analyst says to sell
D.A. Davidson worries that Rivian’s guidance would require the company to see an unusually strong debut of its R2 EV.
FDA Rejects Moderna's mRNA Flu Vaccine Review
The FDA has refused to review Moderna's mRNA flu vaccine, drawing widespread criticism from doctors and creating division within the agency, with Health Secretary Robert F. Kennedy Jr. broadly rejecting the technology.